This is a preview of subscription content, log in via an institution to check access.
Reference
Lee CC, et al. Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Clinical Pharmacology and Therapeutics : 18 Jun 2021. Available from: URL: http://doi.org/10.1002/cpt.2322
Rights and permissions
About this article
Cite this article
Lost Medicare savings due to delayed adalimumab biosimilar marketing. PharmacoEcon Outcomes News 882, 18 (2021). https://doi.org/10.1007/s40274-021-7852-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7852-3